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Parenteral dministration f 
ated with a decrease in arte 
can be clinically im 
clinicians from using intravenous quinidine xcept in inten- 
sive care unit settings (1). In dogs, quinidine attenuates 
vasoconstrictor responses tosympathetic nerve stimulation 
and regional norepinephrine infusion consistent with 
postjunctional alpha-adrenergic blockade, In addition, vaso- 
dilation is seen with local infusion in denervated xtremities, 
indicating a vasodilator effect hat is independent of alpha- 
adrenergic blockade (2).in humans, intravenous quinidine 
sufficient to produce plasma levels of 1.2 mg/liter causes 
forearm vasodilation, attenuates forearm vasoconstrictor 
responses to lower body suction and attenuates the pressor 
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response to imtravenons rc~inepbrine consistent with 
ost~n~~c~ional alph  b ock 
In a recent study in nQrrna~ unmans fro 
trtravenous procainamide was shown to 
tension, forearm vasodilation andattenu 
I vasoconstriction during 
he absence of a direct 
ravenous ~rocainamide 
caused significant decreases in directly recorded effere 
postganglionic muscle sympathetic nerve activity, suggest- 
ing central or ganglionic blockade of sympathetic outflow. 
Ithough procainamide a 
t, they are botb sodiu 
documented ffects on ~os~unctiona~ alpha receptors. We 
therefore recorded irectly efferent postganglionic sympa- 
thetic nerve activity from the peroneal nerve before and 
during intravenous loading with quinidine. Sympathetic 
nerve activity recorded during quinidine loading was com- 
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pared with sympathetic nerve activity during infusion of 
nitroprusside that produced comparable hemodynamic ef- 
fects. Finally, the direct effects of quinidine on forearm 
vasculature were studied with brachial artery infusions of 
quinidine that produced negligible systemic drug levels. 
OdS 
Subjects. We performed 21 experiments in 18 healthy 
men between ihe ages of 19 and 23 years; 3men participated 
in two different experimental protocols. Their mean weight 
(2 SE) was 78.0 2 0.43 kg. No subject smoked or took 
medications. The study protocol was approved by the Hu- 
man Use Committee of the University of Iowa and the 
Clinical Research Center, and informed written consent was 
obtained from all subjects before the experimental session. 
The study design was based on a previous study (3) of the 
effects of procainamidc in normal human subjects. 
Sympathetic nerve ecordings. Multiunit postganglionic 
muscle sympathetic nerve activity was recorded from the 
right or left peroneal nerve at the head of the fibula with 
custom-made tungsten microelectrodes (University of 
Iowa). Microneurographic te hniques developed in Sweden 
were employed (4). 
The nerve signal underwent two-stage amplification (gain 
70,000), rectification, bandpass filtering (700 to 2,000 Hz) 
and integration (resistance-capacitance cir uit; time con- 
stant 0.1 s). The integrated nerve signal was displayed on an 
oscilloscope and recorded on a paper chart recorder (Gould 
ES2000). 
There were several criteria for an acceptable recording: 
I) Weak electrical stimulation through the recording elec- 
trode elicited muscle contiaction but no paresthesias, indi- 
cating that nerve fascicles supplying muscle but not skin had 
been impaled. 2) Stretching the muscles or tendons supplied 
by the impaled fascicle licited afferent mechanoreceptor 
discharges, but stroking skin in the sensory held of the nerve 
produced no response. 3) Volleys or bursts of nerve activity 
appeared intermittently in the nerve signal and increased in
frequency, intensity and amplitude during held expiration 
and during phases 2 and 3 of the Valsalva maneuver. 
Previous tudies have provided evidence that hese bursts of 
activity represent efferent muscle sympathetic nerve activity 
(5). In addition, levels of directly recorded sympathetic 
nerve activity correlate with plasma levels of the sympa- 
thetic neurotransmitter nor pinephrine (6). 
Measurement of forearm blood flow. Right or left forearm 
blood flow was measured by venous occlusion plethysmog- 
raphy. An air-filled latex bladder of known volume and 
compliance was placed around the midforearm and con- 
nected to a low pressure transducer (Validyne, Gould Elec- 
tronics). Venous outflow from the forearm was occluded 
intermittently with a custom-made cuff inflation device 
(Rioengineering, University of Iowa) and hand blood flow 
was exchded with a wrist cuff inflated to suprasystolic 
Pressures; the wrist cti was inflated for 1 min before the 
determination f forearm blood flow. The rate of increase in 
forearm volume nclosed by the bladder during intermittent 
occlusion of venous outflow was taken as the rate of blood 
flow into the enclosed tissues. 
MeasMre~e~E iiral venoms Pressure. Central venous 
pressure was reco directly from a polyetbyle~e catheter 
inserted into an antecubital vein and advanced to an intra- 
thoracic position. The catheter was connected to a pressure 
transducer (Statham P23 ID, Gould Electronics) with the 
midchest as a reference l vel. The waveform was electron- 
ically averaged and recorded on a paper chart recorder 
en&. Arterial pressure was reco 
I-mitt intervals with an aut 
(Physio Control). Heart rate w 
recording of the electrocardiogra 
corded with a bellows strai 
abdomen. 
Drugs. Quinidine gluconate (Lilly), 800 mg, was diluted 
in 50 ml of 5% dextrose in water for intravenous infusion. 
For intraarterial nfusion, 800 mg was diluted in 250 ml of 5% 
dextrose in water. Sodium nitroprusside (Nitropress, 
Abbott), 50 mg, was diluted in 50 ml of 5% dextrose in water 
for intravenous infusion. 
01s. Three sets of experiments were 
Effects of intravenous quiniditte. Eight subjects ( 
age 22.1 + 0.1 years, mean weight 82.2 f 0.9 kg) were 
studied. After placement of perip:ie;al nd central venous 
catheters and microelectrodes for nerve recording, and 
preparation f t for pIet~ysmograpby, the subject 
rested supine for 5 min. Five percent dextrose in water was 
infused at 15 ml/h in the peripheral venous line to maintain 
catheter patency. Five minutes of baseline data were re- 
corded, and forearm blood flow was measured five to seven 
times in the final 2 min. Then the right or left hand (contra- 
lateral to the arm in which flow was measured) was im- 
mersed in ice water for 2 min (cold pressor test). Sympa- 
thetic nerve activity, forearm blood flow and arterial 
pressure were measured during the 2nd min. After an 8-min 
recovery period, quinidine gluconate, 8 mglkg body weight, 
was infused intravenously at a rate of 0.3 mg/kg per min for 
27 min. Arterial nd central venous pressures, ympathetic 
nerve activity and heart rate were averaged over the 23rd 
through the 25th min of the infusion, and the cold pressor 
test was repeated in the 26th and 27th min. Values for 
sympathetic nerve activity, arterial pressure and forearm 
blood flow were taken in the 2nd min of the cold pressor test, 
that is, the 27th min of the infusion. Subjects were admitted 
to the Clinical Research Center for electrocardiographic 
monitoring for 4 h after the study. A IZIead electrocardio- 
gram (KG) was obtained before discharge. 
EJfects ofintraarterial quinidine. Eight subjects (mean age 
21.8 + 0.1 years, mean weight 78.1 2 1.0 kg) were studied. 
After placement of a brachial artery catheter and prepa- 
ration of the ipsilateral forearm for plethysmography, the 
subjects rested quietly for 5min before forearm blood flow 
forearm blood flow was measured at min 2. After an 8611 
recoveiry period, forearm blood Row was measured before 
and during the 2nd min of a 2-min cold 
In&arterial quinidine, 800 mg in 250 ml of 5 
water, was then infused at 7 ml/h (0.37 mg/min) for 10 min, 
and forearm blood flow was measured at 10 min. The 
infusion rate was increased Lo 14 and 28 ml/h (0.74 and 
1.48 mg/min) for 10 min at each dose, and forearm blood flow 
was measured atIQ min. After the 28-mYh 
cold pressor test was performed, and forear 
measured during the 2nd 
Eficts of intravenous nitroprusside. Five subjects (mean 
age 21 .O ? 0.2 years, mean weight 75 + I .3 kg) were studied. 
After placement of peripheral nd central venous cathe- 
ters and microelectrodes fornerve recording, the subjects 
rested quietly for 5 min, and 5 min of baseline data were 
recorded. Nitroprusside, 0.5 lug/kg per min, was then infused 
intravenously for 10 min. Central venous pressure, arterial 
pressure and sympathetic nerve activity were averaged 
during the final 5 min. 
ata analysis. Sympathetic nerve activity was quantified 
by measuring the amplitude of all bursts recorded during the
period of interest. This was done with a digitizing tablet 
connected toan IBM compatible personal computer (Sigma 
Scan, Jandel Scientific). Values for central venous pressure 
were taken from the char’ rzordings at 20-s intervals during 
the period of interest. 
A Student test was used for pairwise comparisons. 
Repeated measures analysis of variance (ANOVA) was used 
to compare three or more within-group measurements. 
ScheWs F test was used when ANOVA indicated signifi- 
cant differences. Significance was accepted at p < 0.05. 
Values are expressed as mean values + SE. 
1. Original Kmm.lings and calculated levels of symQatb~tic 
e activity (SNA), ~let~ysmo~rapb~c trac’ and ~x~easures of 
load flow and values for heart rate ( 
central venous pressure KY/P) i 
nd after intravenotis NV) infusion 
body weight. Quinidine decreased arterial an 
WCS and increased forearm blood Row, heart rate and sy 
nerve activity. 
Figure 1 shows original recordings of sy 
aclivity and ~l~~~ysrnog~ 
and data from one subje 
nous adm~nistra~ioa of inidine. There were s 
thetic nerve activity. 
Table 1 shows mean values for systolic, diastolic and 
mean arterial pressures; central venous pressure; h art rate 
and sympathetic nerve activity measured before and at the 
end of loading with intravenous quinidine. The q~inid~~e 
level measured in the 27th min of the infusion was 3.5 f 
0.6 cLg/ml. Quinidine caused significant decreases in diastolic 
and mean arterial pressure, central venous pressure and 
forearm vascular resistance, as well as a significant i crease 
in heart rate, forearm blood flow and sympathetic nerve 
activity (Fig. 1). 
Figure 2 shows the effects of intravenous 
changes in sympathetic nerve activity and 
pressure provoked by rhe cold 
nerve activity was ’ nificantly reduced 
quinidine (Table 1). ean arterial pressu 
min of the cold pressor test 
intravenous administration 0 
activity was significantly increased after quinidine and in- 
creased further during the cold pressor test. Absolute in- 
creases in sympathetic nerve activity during the cold pressor 
test were similar before and after quinidine. 
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Table 1. Effects of Intravenous Quinidine 
After Quinidine 
Baseline (8 mtig) 
Heart rate (beats/min) 67 x 4 77 + 5* 
Systolic AP (mm Hg) 121 t 5 127 + 6 
Diastolic AP (mm Hg) 683 61 + j* 
Mean AP (mm Hg) 87 f 3 83 + 3* 
CVP (mm Hg) 6.3 + 0.6 5.0 + 0.7* 
FBF (mlknin per dl) 3.3 + 0.5 4.2 + 0.8* 
FVR (units) 32.2 i: 5.5 25.3 2 4.7* 
SNA (U/min) 288 2 70 660 + 151’ 
*p < O-05 compared with baseline. Values are mean t SE. AP = arterial 
pressure; CVP = central venous pressure; FBF = forearm blood flow; 
FVR = forearm vascular resistance; SNA = sympathetic nerve activity. 
Effects of intraarterial quini inc. Figure 3 shows the 
effects ofquinidine or 5% dextrose in water (vehicle) infused 
directly into the brachial artery on ipsilateral forearm vas- 
cular resistance. Intraarterial vehicle was without etfect. 
I=Iowever, intraarterial quinidine caused dose-related de- 
creases in forearm vascular esistance. The cumulative 
Figure 2. Bar graph showing the effect of intravenous (IV) quinidine 
on baseline (white bars) mean arterial pressure (MAP) and sympa- 
thetic nerve activity (SNA) and the effects of the cold pressor test 
(black bars) on these variables ineight subjects. As shown in Table 
1, mean arterial pressure decreased and sympathetic nerve activity 
increased significantly after quinidine. Although increases in mean 
arterial pressure and sympathetic nerve activity during the cold 
pressor iest were comparable before and after quinidine, absolure 
levels of sympathetic nerve activity were higher and mean arterial 
pressure lower during the cold pressor test after quinidine. Values 
are mean value +- SE. Asterisk indicates a p value of <O.OS. 
1200 
SNA 
(unlWmln) 6oo 
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Figure 3. Line graph comparing the effects of int~aa~~~a~ vehicle 
(5% dextrose in water) and i~traaa~e~ial qM~~~d~n~ on i~si~at~~ai 
forearm vascular resistan.cc in eight subjects. Dose I was 
0.37 (7 ml/h), dose 2 was 0.74 mg/min (14 ml/h) and dose 3 was 
1.48 mg/min (28 ml/h). Quinidine cause dose-dependent forearm 
vasodilation, whereas vehicle was without effect. Systemic quini- 
dine levels at the end of the third ose averaged 0.I p/ml (n = 4). 
Values are mean values + SE. Asterisk indicates a p value of <0.0.5. 
quinidine dose at the end of the first, second and third 
infusions was 3.7, 11.1 and 25.9 mg, respectively. There 
were no changes in arterial or central venous pressmes or 
heart rate during intraarterial q~inidi~e, and t ean sys- 
temic quinidine level after the third intraarterial infusion 
measured in four subjects was 0.1 &ml. 
Figure 4 shows responses to the cold pressor test per- 
formed after the third intraarterial nfusions of vehicle and 
quinidine. ~~traarte~aI q~~~~d~ e redued baseline forearm 
vascular resistance (Fig. 3). During the infusion of vehicle, 
contralateral h nd immersion water tended to increase 
forearm vascular esistance. ever, during quinidine 
Figure 4. Bar graph showing the effects of intraarterial (IA) vehicle 
and quinidine on baseline l vels (white bars) of forearm vascular 
resistance (FVR) measured near the end of the third dose and 
changes ofthis variable during the cold pressor test (black bars) in 
eight subjects. During vehicle infusion forearm vascular resistance 
tended to increase during the cold pressor test; however, during 
quinidine infusion, the cold pressor test provoked a small but 
statistically significant decrease in forearm vascular esistance. 
Asterisk indicates a p value of ~0.05. Values are mean value + SE. 
During 
IA Vehicle 
During 
IA Quinidine 
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1415 
prusside on sympatheti 
icant difference in levels of sympathetic nerve activity during the 
two infusions; statistical outcome was unaffected by exclusion of the 
one outlier value during quinidilie iaf~sio~. tktcris 
overlappiag data points. 
infhm, the cold pressor test further decreased an already 
signilkanitly decreased forearm vascular resistance. 
ases in arterial and 
central venous pressures. To investigate this ~oss~bi~ity, 
we compared levels of sympathetic nerve activity during 
intravenous quinidine (n = 8) with levels during nitro- 
prusside infusion (n = 5) th caused similar hemody~amic 
changes. Systolic arterial ressure was uncha 
either drug. There were co 
pressure (nitroprusside -7.2 L 1.0 m 
2 2.2 mm Hg) and central venous pressure (nitroprusside 
- 1.5 2 0.3 mm Hg, quinidine - I .3 +- 0.6 mm Hg). Increases 
in heart rate tended to be greater during quinidine than 
during ~~tropr~sside administration (11 f 2 vs. 7 -C 4 beats 
per minute, respectively, p = NS). Figure 5 shows individual 
and mean values for sympathetic nerve activity expressed as
a percent of baseline during intravenous quinidine and 
nitroprusside. ‘There was no significant difference in the 
extent of sympathetic excitation provoked by the two drugs. 
One subject had marked increases in sympathetic nerve 
activity during quinidine infusion; his hemodynamic re- 
sponses were not significantly different from those of other 
subjects. Inclusion or exclusion of this subject’s data did not 
affect statistical outcome. 
s, The mech- 
anisms by which membrane-active antiarrhythmic agents 
produce adverse hemodynamic effects are varied. Disopyra- 
mide has been reported to cause substantial decreases in
cardiac output and arterial pressure because of its negative 
ay criuse direct smooth 
ax, it also decrea 
been asclibsd to a direct negative inot 
drug (9). In a recent study we she 
n addition, vasodiiat~o~ observe 
de, quinidine causes local vaso- 
f vasocQ~strict0~ responses to 
sympathoexcitatory stimuli when infused irectly into the 
brachial a Animal studies have suggested that quini- 
-adrenergic antagonist (2). Intact ani 
in vitro studies have suggested t ine is s~bsta~tia~~y 
more potent in blocking alpha,- than alpha,-receptors. In 
addition, it may have a second site of action in vascdar 
creases m symp 
sion could result in part fr 
tation. Cinchonism, a corn 
that is, tinnitus, delirium and psychosis (11). ~u~bermore, 
central alpha,-rece r antagonism increases ympathetic 
nerve activity (12). spite these considerations, quinidine- 
induced increases insympathetic nerve activity were com- 
parable with those seen during equihypotensive  
~itroprusside, anagent with no known direct 
sympathetic nerve function. These results uggest that aug- 
mented sympathetic drive during quinidine 
ably secondary tobaroretlex mechanisms. 
basis of the present experiments, we cannot exclude the 
possibihy that decreases in cardiac ontractility contributed 
to the sympathoexcitatio~ observed uring q~j~~dine fu- 
sio 
e. Q~im~diae c used fore- 
arm vasodilation when ad nistered systemically ordirect1 
into the brachial artery. ean arterial pressure decrease 
significantly, and levels of mean arterial pressure achieved 
during the cold pressor test were significantly lower during 
intravenous quinidine administration. I  addition, forearm 
vasoconstriction during the cold pressor test was virtually 
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reversed during intraarterial infusion. These results are 
consistent with the notion that quinidine blocks sympathetic 
vasoconstrictor responses at the level of the neuroeffector 
junction. Similarly, a previous study (13) demonstrated 
attenuated blood pressure responses to exercise during 
quinidine treatment in normal volunteers. Increases in heart 
rate and cardiac output during the cold pressor test unac- 
companied by peripheral vasoconstriction would be ex- 
pected to lead to increased peripheral blood flow. as was 
seen during intraarterial quinidine infusion. In contrast. 
procainamide attenuates sympathetic responses at or proxi- 
mal to the postganglionic nerve. 
Clinical implications, When given intravenously, quini- 
dine and procainamide cause substantially greater hypoten- 
sion than when given orally in doses that achieve similar 
blood levels. The mechAsms by which these disparate 
hemodynamic effects occur arc not clear and were not 
specifically evaluated in the present study. It is possible that 
activation of humoral compensatory mechanisms (such as 
the renin-angiotensin-aldosterone system) during long-term 
oral treatment attenuates the hypotensive effect of these 
drugs, It is also possible that during maintenance oral 
treatment, vasoactive metabolites accumulate that tend to 
support blood pressure. This possibility may be especially 
relevant to procainamide because n-acetyl procainamide 
may have significant positive inotropic effects (14). These 
and other potential mechanisms warrant further study. 
Patients with impaired sympathetic nerve function due to 
either disease processes or medications are very susceptible 
10 the hypotensive effects of vasodilator drugs (15). It is 
possible that such patients would tolerate procainamide 
better hemodynamically than quinidine because the vasodi- 
later effect of procainamide depends at least in part on the 
withdrawal of sympathetic activity, a hcmodynamic buffer 
that is already impaired in these patients, Direct vasodilators 
(like qdnidine) may cause disastrous decreases in blood 
pressure in patients with impaired sympathetic buffer mech- 
anisms (15). Careful infusion of quinidine and procainamide 
in patients with autonomic failure could be performed to test 
this hypothesis. 
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